Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

NCT03632759 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medications liraglutide or golimumab can help preserve insulin-producing beta cell function in adults with longstanding type 1 diabetes.

Status Completed The study has finished.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 16 people

Who can join Ages 18–50 · all sexes

Timeline Started 2018-08 · est. completion 2021-11

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT03632759 ↗

Description as written by the study sponsor.

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Treatments tested

Liraglutide also known as Victoza Drug

Participants will receive subcutaneous (SC) liraglutide for 8 weeks
Golimumab also known as SIMPONI Drug

Participants will receive subcutaneous (SC) golimumab for 8 weeks

Main thing measured	Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.
Sponsor	Carla Greenbaum, MD
Conditions studied	Type 1 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03632759 ↗